Coronavirus Update - 14th October 2020

Despite the recent rises in Covid-19 cases throughout the UK and Europe, Arcinova remains open for business at full capacity as we have done throughout this pandemic. As the situation continues to evolve, we will keep all our customers and stakeholders informed of our activities through this web-page which is updated on a regular basis.

We would like to take this opportunity to thank our clients and staff for their continued support over this period of restricted movement. 

We fully comply with all government guidance on minimising the risks of COVID-19 and have published our risk assessment here

Arcinova Releases Latest Case Study

The challenge - to develop stable sterile formulations of a drug substance for intravenous administration in phase I clinical trials.  The drug substance, intended for the treatment of CNS (Central Nervous System) related disorders, was physically and chemically unstable in aqueous media and there was a requirement for the product to be delivered both as a bolus and maintenance dose over an extended period of several days.

Find out more about how we solved the issue here




Discover how Arcinova can help

We provide a fully integrated approach to drug development, speak to our team and discover how we can help you fast forward to market.

GET IN TOUCH